Search | Clinical Trials Finder

Conditions: Hepatocellular Cancer, Hepatocellular Carcinoma, Metastatic Hepatocellular Carcinoma
Interventions: durvalumab, Doxorubicin-Eluting Beads, TACE, bevacizumab, Tremelimumab; Drug · Procedure
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years to 120 Years
Enrollment: 27 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2027
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Biliary Tract Neoplasms, Cholangiocarcinoma, Bile Duct Cancer, Liver Cancer, Gallbladder Cancer
Interventions: Pembrolizumab (MK-3475), Oxaliplatin, Capecitabine; Biological · Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2021
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Biliary Cancer, Bile Duct Cancer, Cancer of the Bile Duct
Interventions: oxaliplatin, capecitabine, Keytruda, CDX-1140; Drug · Biological
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years to 120 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2042
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Biliary Tract Carcinoma
Interventions: Pembrolizumab, Gemcitabine, Cisplatin, Placebo; Biological · Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years and older
Enrollment: 1,069 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2025
U.S. locations: 18
States / cities: Birmingham, Alabama • La Jolla, California • Los Angeles, California + 14 more

Conditions: Biliary Tract Cancer
Interventions: Nivolumab, DKN-01; Drug
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years and older
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 2
States / cities: Boston, Massachusetts

Conditions: Biliary Tract Cancer (BTC), Colorectal Cancer (CRC), Endometrial Cancer, Gastroesophageal Cancer (GC), Ovarian Cancer, Solid Tumors
Interventions: INCB001158, Oxaliplatin, Leucovorin, 5-Fluorouracil, Gemcitabine, Cisplatin, Paclitaxel; Drug
Lead sponsor: Incyte Corporation; Industry
Eligibility: 18 Years and older
Enrollment: 149 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2022
U.S. locations: 6
States / cities: Birmingham, Alabama • Mobile, Alabama • Sacramento, California + 3 more

Conditions: HER2 Mutation-Related Tumors, HER2 Amplified Solid Tumors
Interventions: ARX788; Drug
Lead sponsor: Ambrx, Inc.; Industry
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 2
States / cities: Miami Beach, Florida • Kansas City, Missouri

Conditions: Bile Duct Cancer, Biliary Cancer, Biliary Tract Neoplasms, Cholangiocarcinoma
Interventions: Trametinib, Hydroxychloroquine; Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Solid Tumor, Advanced Cancer, Metastatic Cancer, Gastric Cancer, Gastroesophageal Junction Carcinoma, Esophageal Adenocarcinoma, PDAC - Pancreatic Ductal Adenocarcinoma, Biliary Tract Cancer (BTC)
Interventions: TJ033721 (givastomig), TJ033721 (givastomig) , nivolumab, chemotherapy, TJ033721 (givastomig), chemotherapy, TJ033721 (givastomig), durvalumab, chemotherapy; Drug
Lead sponsor: I-Mab Biopharma US Limited; Industry
Eligibility: 18 Years and older
Enrollment: 330 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2027
U.S. locations: 11
States / cities: Orange, California • Aurora, Colorado • Layfayette, Indiana + 7 more

Conditions: Biliary Tract Neoplasms
Interventions: Durvalumab, Placebo; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 130 Years
Enrollment: 810 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2027
U.S. locations: 15
States / cities: Los Angeles, California • Orange, California • Washington D.C., District of Columbia + 12 more

Conditions: Advanced Solid Tumors, Ewing Sarcoma, Hepatocellular Carcinoma (HCC), Biliary Tract Cancer (BTC)
Interventions: ST-01156; Drug
Lead sponsor: SEED Therapeutics, Inc.; Industry
Eligibility: 16 Years and older
Enrollment: 171 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 6
States / cities: Duarte, California • Newport Beach, California • Boston, Massachusetts + 2 more

Conditions: Biliary Tract Cancer (BTC)
Interventions: telotristat ethyl; Drug
Lead sponsor: TerSera Therapeutics LLC; Industry
Eligibility: 18 Years and older
Enrollment: 53 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 14
States / cities: Gilbert, Arizona • Fullerton, California • Gainesville, Florida + 11 more

Conditions: Cancer
Interventions: Dabrafenib, Trametinib; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 206 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2021
U.S. locations: 8
States / cities: Little Rock, Arkansas • Santa Monica, California • Bethesda, Maryland + 4 more

Conditions: Advanced or Metastatic Solid Tumor
Interventions: PLN-101095, Pembrolizumab; Drug
Lead sponsor: Pliant Therapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 124 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2030
U.S. locations: 6
States / cities: New Haven, Connecticut • Atlanta, Georgia • Grand Rapids, Michigan + 3 more

Conditions: Gastric or Gastroesophageal Junction Adenocarcinoma, Pancreatic Ductal Adenocarcinoma, Biliary Tract Cancer (BTC)
Interventions: Spevatamig (PT886), Paclitaxel, Gemcitabine, Abraxane, KEYTRUDA® (pembrolizumab), FOLFOX, CAPOX, FOLFIRINOX; Drug
Lead sponsor: Phanes Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 258 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2028
U.S. locations: 11
States / cities: Duarte, California • Los Angeles, California • Denver, Colorado + 8 more

Conditions: Biliary Tract Cancer (BTC)
Interventions: D07001-Softgel Capsules, Placebo, Capecitabine; Drug · Combination Product
Lead sponsor: InnoPharmax Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 240 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 2
States / cities: Miami Beach, Florida • Cleveland, Ohio

Conditions: Biliary Tract Cancer, Cholangiocarcinoma, Gallbladder Cancer
Interventions: M7824, Placebo, Gemcitabine, Cisplatin; Drug
Lead sponsor: EMD Serono Research & Development Institute, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 309 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 12
States / cities: Chandler, Arizona • Gilbert, Arizona • Phoenix, Arizona + 9 more

Conditions: Biliary Tract Neoplasms, Liver Cancer, Hepatocellular Carcinoma, Cholangiocarcinoma, Bile Duct Cancer
Interventions: Durvalumab, Tremelimumab, Trans-arterial Catheter Chemoembolization (TACE), Radiofrequency Ablation (RFA), Cryoablation; Drug · Procedure
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 54 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2022
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Heptocellular Cancer, Biliary Tract Neoplasms, Liver Cancer, Hepatocellular Carcinoma, Biliary Cancer
Interventions: Tremelimumab, RFA, TACE, Cryoablation; Drug · Procedure
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years to 99 Years
Enrollment: 61 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2017
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: HER2-expressing Gastrointestinal Cancers, Including Gastroesophageal Adenocarcinoma, Biliary Tract Cancer, and Colorectal Cancer
Interventions: ZW25 (Zanidatamab), Capecitabine, Cisplatin, Fluorouracil, Leucovorin, Oxaliplatin, Bevacizumab, Gemcitabine; Drug
Lead sponsor: Jazz Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 74 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2025
U.S. locations: 11
States / cities: Los Angeles, California • Newport Beach, California • Tampa, Florida + 8 more

Conditions: Advanced Biliary Tract Cancer, Biliary Tract Cancer (BTC)
Interventions: Nanvuranlat, Physician's Best Choice; Drug · Other
Lead sponsor: J-Pharma Co., Ltd.; Industry
Eligibility: 18 Years and older
Enrollment: 480 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 18
States / cities: Duarte, California • Orange, California • Santa Monica, California + 15 more

Conditions: Biliary Tract Cancers
Interventions: mBTC vax [0.3 - 2.4 mg peptide + 0.5 mg Poly-ICLC (Hiltonol)], Durvalumab, Tremelimumab; Drug
Lead sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; Other
Eligibility: 18 Years and older
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Hepatocellular Carcinoma, Biliary Tract Cancer
Interventions: RP2, Bevacizumab, Atezolizumab, Durvalumab, RP2 Monotherapy; Biological
Lead sponsor: Replimune, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 12
States / cities: Beverly Hills, California • La Jolla, California • Miami, Florida + 9 more

Conditions: Solid Tumor Cancer, Locally Advanced, Metastatic Solid Tumors, Lung Cancers, Epithelial Tumor, Biliary Tract Cancer (BTC), Urothelial Cancer, Nasopharyngeal Cancers
Interventions: AVZO-1418, Combination Agent 1, Combination Agent 2; Drug
Lead sponsor: Avenzo Therapeutics, Inc.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 480 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2030
U.S. locations: 18
States / cities: Gilbert, Arizona • Los Angeles, California • Denver, Colorado + 15 more

Search by objective public record fields.

Combined Treatment of Durvalumab, Bevacizumab, Tremelimumab and Transarterial Chemoembolization (TACE) in Subjects With Hepatocellular Carcinoma or Biliary Tract Carcinoma

Pembrolizumab, a Monoclonal Antibody Against PD-1, in Combination With Capecitabine and Oxaliplatin (CAPOX) in People With Advanced Biliary Tract Carcinoma (BTC)

A Study of CDX-1140, a CD40 Agonist, in Combination With Capecitabine and Oxaliplatin (CAPOX) and Keytruda in Subjects With Biliary Tract Carcinoma (BTC)

Pembrolizumab (MK-3475) Plus Gemcitabine/Cisplatin Versus Placebo Plus Gemcitabine/Cisplatin for First-Line Advanced and/or Unresectable Biliary Tract Carcinoma (BTC) (MK-3475-966/KEYNOTE-966)

Study of the Combination of DKN-01 and Nivolumab in Previously Treated Patients With Advanced Biliary Tract Cancer (BTC)

A Phase 1/2 Study of INCB001158 in Combination With Chemotherapy in Subjects With Solid Tumors

ARX788 in Selected HER2-mutated or HER2-amplified/Overexpressed Solid Tumors (ACE-Pan Tumor-02)

Combination of Trametinib (MEK Inhibitor) and Hydroxychloroquine (HCQ) (Autophagy Inhibitor) in Patients With KRAS Mutation Refractory Bile Tract Carcinoma (BTC).

Study of TJ033721 (Givastomig) in Subjects With Advanced or Metastatic Solid Tumors

Durvalumab or Placebo in Combination With Gemcitabine/Cisplatin in Patients With 1st Line Advanced Biliary Tract Cancer (TOPAZ-1)

A Phase 1/1B Study of ST-01156, a Small Molecule RBM39 Degrader, in Patients With Advanced Solid Malignancies

A Safety and Efficacy Study of XERMELO® + First-line Chemotherapy in Patients With Advanced Biliary Tract Cancer

Efficacy and Safety of the Combination Therapy of Dabrafenib and Trametinib in Subjects With BRAF V600E- Mutated Rare Cancers

A Phase 1 Study of PLN-101095 in Adults With Advanced or Metastatic Solid Tumors

Spevatamig (PT886) as Monotherapy or in Combination With Chemo and/or ICI, for the Treatment of Patients With Advanced Gastric, Gastroesophageal Junction, Pancreatic Ductal or Biliary Tract Carcinomas (the TWINPEAK Study)

D07001 Softgel-Capsules and Capecitabine Combination Therapy in Patients With Advanced Biliary Tract Cancer

Gemcitabine Plus Cisplatin With or Without Bintrafusp Alfa (M7824) in Participants With 1L BTC

A Pilot Study of Combined Immune Checkpoint Inhibition in Combination With Ablative Therapies in Subjects With Hepatocellular Carcinoma (HCC) or Biliary Tract Carcinomas (BTC)

Tremelimumab With Chemoembolization or Ablation for Liver Cancer

A Safety and Efficacy Study of ZW25 (Zanidatamab) Plus Combination Chemotherapy in HER2-expressing Gastrointestinal Cancers, Including Gastroesophageal Adenocarcinoma, Biliary Tract Cancer, and Colorectal Cancer

A Study to Select a Dose Regimen (Part A) and to Investigate Overall Survival (Part B) With Nanvuranlat Compared With Physician's Best Choice in Participants Aged 18 Years or Older With Biliary Tract Cancer

Targeting Driver Oncogenes With a Peptide Vaccine Plus Durvalumab and Tremelimumab for Patients With Biliary Tract Cancers (BTC)

Study of RP2 in Combination With Second-line Therapy in Patients With Locally Advanced or Metastatic HCC

AVENTINE-1: Study of AVZO-1418 as a Single Agent and in Combination Therapy in Patients With Locally Advanced or Metastatic Solid Tumors (AVZO-1418-1001)